<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245527</url>
  </required_header>
  <id_info>
    <org_study_id>2216</org_study_id>
    <nct_id>NCT04245527</nct_id>
  </id_info>
  <brief_title>Use of Infrared Photomodulation for Hormonal Balance (Joovvin' for Hormonal Health)</brief_title>
  <official_title>Joovvin' for Hormonal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProofPilot</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Joovv</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProofPilot</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      8-week pilot study looking at the impact of Joovv's infrared photo modulation product on male
      and female hormone levels.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Enrolled individuals will receive a Joovv solo for the 8 week study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Testosterone Change</measure>
    <time_frame>baseline to week 8</time_frame>
    <description>in males, change from baseline to week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of thyroid-stimulating hormone (TSH)</measure>
    <time_frame>baseline to week 8</time_frame>
    <description>in females change in estrogen and progesterone from baseline to week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self report general wellness</measure>
    <time_frame>baseline to week 8</time_frame>
    <description>series of questions at baseline and week 8 on general wellness (modified Short Form-36)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Testosterone Deficiency</condition>
  <condition>Estrogen Deficiency</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 minutes Joovv Solo every day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Joovv Infrared Light Device</intervention_name>
    <description>Joovv is the leading manufacturer of personal, in-home red light therapy devices</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  United States resident

        Exclusion Criteria:

          -  current Joovv or other photomodulation therapy user

          -  under medical supervision for medically treatable illness

          -  significant travel during study period

          -  use of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew M Amsden</last_name>
    <phone>3232844626</phone>
    <email>crew@proofpilot.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ProofPilot (Virtual Study: https://p.proofpilot.com)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 25, 2020</study_first_submitted>
  <study_first_submitted_qc>January 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>there is no current plan to make IPD available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

